Abstract
Background: The discriminative utility of the neonatal sequential organ failure assessment (nSOFA) for early-onset sepsis (EOS) mortality in the neonatal intensive care unit (NICU) is unknown. Objectives: The objective of the study was to determine the utility of nSOFA for EOS mortality. Methods: Multicenter, retrospective cohort study of NICU patients with EOS between 2012 and 2023. nSOFA scores of survivors and non-survivors were compared, and area under the receiver operating characteristics curve (AUROC) for mortality was calculated. Results: 104 subjects were identified (88 lived, 16 died). AUROC at blood culture collection (T0), 6 h after collection (T6), and the maximum nSOFA at T0 or T6 (T0–6max) were 0.76 (95% CI: 0.62, 0.91), 0.89 (0.80, 0.99), and 0.87 (0.77, 0.97), respectively. Analyses restricted to birthweight (<1.5, <1 kg) or gestational age (<32, <29 week) cutoffs revealed AUROC ranges of 0.86–0.92 for T6 and 0.82–0.84 for T0–6max. Conclusions: The nSOFA showed good-to-excellent discrimination of mortality among infants with EOS in the NICU.
Journal Section:
Brief Report
References
1.
Puopolo KM, Benitz WE, Zaoutis TE, Committee On F, NewbornCommittee On Infectious D. Management of neonates born at ≤34 6/7 Weeks’ gestation with suspected or proven early-onset bacterial sepsis. Pediatrics. 2018 Dec;142(6):e20182896.
2.
Stoll BJ, Puopolo KM, Hansen NI, Sanchez PJ, Bell EF, Carlo WA, et al. Early-onset neonatal sepsis 2015 to 2017, the rise of Escherichia coli, and the need for novel prevention strategies. JAMA Pediatr. 2020 Jul 1;174(7):e200593.
3.
Mukhopadhyay S, Puopolo KM, Hansen NI, Lorch SA, DeMauro SB, Greenberg RG, et al. Impact of early-onset sepsis and antibiotic use on death or survival with neurodevelopmental impairment at 2 Years of age among extremely preterm infants. J Pediatr. 2020 Jun;221:39–46 e5.
4.
Wynn JL, Polin RA. A neonatal sequential organ failure assessment score predicts mortality to late-onset sepsis in preterm very low birth weight infants. Pediatr Res. 2020 Jul;88(1):85–90.
5.
Fleiss N, Coggins SA, Lewis AN, Zeigler A, Cooksey KE, Walker LA, et al. Evaluation of the neonatal sequential organ failure assessment and mortality risk in preterm infants with late-onset infection. JAMA Netw Open. 2021 Feb 1;4(2):e2036518.
6.
Wynn JL, Mayampurath A, Carey K, Slattery S, Andrews B, Sanchez-Pinto LN. Multicenter validation of the neonatal sequential organ failure assessment score for prognosis in the neonatal intensive care unit. J Pediatr. 2021 Sep;236:297–300 e1.
7.
Lewis AN, de la Cruz D, Wynn JL, Frazer LC, Yakah W, Martin CR, et al. Evaluation of the neonatal sequential organ failure assessment and mortality risk in preterm infants with necrotizing enterocolitis. Neonatology. 2022;119(3):334–44.
8.
Wynn JL, Wong HR, Shanley TP, Bizzarro MJ, Saiman L, Polin RA. Time for a neonatal-specific consensus definition for sepsis. Pediatr Crit Care Med. 2014 Jul;15(6):523–8.
9.
Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med. 2002 Jul 25;347(4):240–7.
10.
Wynn JL, Kelly MS, Benjamin DK, Clark RH, Greenberg R, Benjamin DKJr., et al. Timing of multiorgan dysfunction among hospitalized infants with fatal fulminant sepsis. Am J Perinatol. 2017 Jun;34(7):633–9.
11.
Lavilla OC, Aziz KB, Lure AC, Gipson D, de la Cruz D, Wynn JL. Hourly kinetics of critical organ dysfunction in extremely preterm infants. Am J Respir Crit Care Med. 2022 Jan 1;205(1):75–87.
12.
Puopolo KM, Lynfield R, Cummings JJ, Committee On F, NewbornCommittee On Infectious D. Management of infants at risk for group B streptococcal disease. Pediatrics. 2019 Aug;144(2):e20191881.
13.
Duggan HL, Chow SSW, Austin NC, Shah PS, Lui K, Tan K, et al. Early-onset sepsis in very preterm neonates in Australia and New Zealand, 2007–2018. Arch Dis Child Fetal Neonatal Ed. 2023 Jan;108(1):31–7.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
